DNLI vs. PRTA, RGNX, CYTK, QGEN, RGEN, PCVX, RVMD, EXEL, HALO, and CRSP
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Prothena (PRTA), REGENXBIO (RGNX), Cytokinetics (CYTK), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), and CRISPR Therapeutics (CRSP). These companies are all part of the "medical" sector.
Denali Therapeutics (NASDAQ:DNLI) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Denali Therapeutics had 4 more articles in the media than Prothena. MarketBeat recorded 8 mentions for Denali Therapeutics and 4 mentions for Prothena. Denali Therapeutics' average media sentiment score of 0.79 beat Prothena's score of 0.63 indicating that Denali Therapeutics is being referred to more favorably in the media.
Denali Therapeutics presently has a consensus target price of $40.22, suggesting a potential upside of 93.66%. Prothena has a consensus target price of $67.00, suggesting a potential upside of 217.08%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Denali Therapeutics.
Denali Therapeutics has a net margin of -36.51% compared to Prothena's net margin of -193.17%. Denali Therapeutics' return on equity of -11.46% beat Prothena's return on equity.
92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by company insiders. Comparatively, 28.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Prothena received 161 more outperform votes than Denali Therapeutics when rated by MarketBeat users. Likewise, 70.67% of users gave Prothena an outperform vote while only 67.43% of users gave Denali Therapeutics an outperform vote.
Denali Therapeutics has higher revenue and earnings than Prothena. Denali Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Denali Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.
Summary
Denali Therapeutics beats Prothena on 11 of the 18 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
